Double-blind placebo-controlled parallel-group study to evaluate the safety and efficacy of two doses of oral Dalfampridine extended release tablets (5 mg and 10 mg twice daily) in patients with Multiple Sclerosis
- Type of Study
- Neuroscience - Multiple Sclerosis
- Short Description
To evaluate the efficacy dalfampridine-ER given 5 mg twice daily, compared to 10 mg twice daily and placebo. Secondary objective is to see how peak consenration of the study medication collarate with improvement of walking speed as measured by the Timed 25-Foot Walk (T25FW) in patients diagnosed with multiple sclerosis
- Principal Investigator
- Angeli Mayadev, MD
- Eligibility Notes
- 18 to 70 years of age, inclusive
- MS-related walking impairment
- Any history of seizures.
- Onset of an MS exacerbation within 60 days.
- Contact Name
- Yuriko Courtney
- (206) 320-2647